Skip to main content

Table 4 Comparison of immunization effects on extrauterine prevention alone for newborns of HBsAg- and/or HBeAg-positive women &

From: Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials

Pregnancy infection status

Newborn infection status

Detective time

Number of included studies

Sample size

Meta-RR (95% CI)

Total (HBsAg+ and/or HBeAg+)

HBsAg+

At birth

7

1061

0.66(0.52,0.84) 3)

7-12 month

12

1451

0.54(0.42,0.69) 3)

>12 month

7

1214

0.54(0.42,0.69) 3)

HBsAb+

At birth

4

291

2.12(1.66,2.70) 3)

7-12 month

8

566

1.12(1.03,1.22) 3)

>12 month

5

502

1.06(0.96,1.16)3)

Subgroup (HBsAg+ and HBeAg+)

HBsAg+

At birth

7

782

0.75(0.57,0.99) 3)

7-12 month

12

1095

0.56(0.42,0.75) 3)

>12 month

7

889

0.55(0.41,0.75) 3)

HBsAb+

At birth

4

291

3.25(1.35,7.83) 2)

7-12 month

9

443

1.14(1.05,1.24) 3)

>12 month

5

502

1.06(0.96,1.16)3)

Subgroup (HBsAg+ and HBeAg-)

HBsAg+

At birth

1

279

0.59(0.34,1.02)3)

7-12 month

3

356

0.64(0.39,1.06)3)

>12 month

2

325

0.63(0.41,0.97) 3)

Subgroup (low + unclear bias)

HBsAg+

At birth

4

348

0.82(0.58,1.18)3)

7-12 month

10

739

0.56(0.38,0.82) 3)

>12 month

4

400

0.43(0.23,0.82) 3)

HBsAb+

At birth

3

221

4.21(2.70,6.57) 3)

7-12 month

8

566

1.12(1.03,1.22) 3)

>12 month

4

400

1.05(0.93,1.17)3)

Subgroup (high risk bias)

HBsAg+

At birth

3

713

0.58(0.42,0.81) 3)

7-12 month

2

712

0.53(0.39,0.72) 3)

>12 month

3

814

0.56(0.43,0.73) 3)

HBsAb+

At birth

1

70

0.91(0.76,1.09)

7-12 month

-

-

-

>12 month

1

102

1.09(0.93,1.27)

  1. &(Mother: none/Infants: HBIG + vaccine) vs (Mother: none/Infants: vaccine); 2)Random effects model, inverse variance method; 3)Fixed effects model, Mantel-Haenszel method; values in boldface indicate statistical significance (P < 0.05).